According to its introduction, Shanghai Jiuqiancheng Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has signed a technology implementation license, transfer, and cooperative development contract with ChironPharma, Inc. in the United States. The two parties have reached a technology sharing cooperation and completed a milestone payment of 4 million US dollars for the indications for heart failure after the opening of cell therapy for myocardial infarction (hereinafter referred to as the "myocardial infarction project") and the treatment of subacute sequelae after cerebral infarction (hereinafter referred to as the "cerebral infarction project"). At present, two projects have obtained clinical approval from the US FDA. Among them, the myocardial infarction project has completed Phase I clinical research and has entered Phase II clinical research. The cerebral infarction project has entered Phase 1/2a clinical research. The target implementation area of this project is China (including Chinese Mainland, Hong Kong, Macao, excluding Taiwan, China).

 

 

 

Cell therapy is a method of delivering functional or enhanced live cells as drugs into the patient's body, replacing diseased, damaged, and degenerated cells, clearing abnormal and diseased cells, or regulating the imbalance of pathological tissues to achieve tissue regeneration, repair, or disease treatment. Compared with small and large molecule drugs, the mechanism of action (MOA) of cells as a novel drug involves cell replacement, cell clearance, and cell regulation from the source. In addition, cell drugs have in vivo functional plasticity, breaking through the limitations of existing drug treatments.

 

 

 

In recent years, driven by favorable policies, technological advancements, and expanding market demand, the cell therapy industry has flourished and shown tremendous development prospects, becoming a new track for the biopharmaceutical industry. According to data predictions, the global market size for stem cell therapy is expected to exceed 226 billion yuan by 2030, with a compound annual growth rate of 13.73%. In this context, numerous investors and companies have entered the market in an attempt to grab a piece of the pie.

 

 

 

According to the information, Chengda Pharmaceutical, which announced its entry, is mainly committed to providing key pharmaceutical intermediate CDMO services for multinational pharmaceutical companies and pharmaceutical research and development institutions, and engaged in the research and development, production, and sales of L-carnitine series products. The terminal drugs served by the company involve anti-tumor, AIDS, hepatitis B, hepatitis C, myelofibrosis, epilepsy, Parkinson's disease and other treatment fields.

 

 

 

Looking ahead to the future, the company stated that it will continue to deepen its research and development of small molecule drugs, continuously increase its R&D innovation efforts, continuously improve its efficient R&D and manufacturing service levels, and comprehensively enhance its multi link and comprehensive CDMO R&D customized service capabilities in segmented fields such as drug preclinical research, clinical research, and commercial production. The company will actively expand its business in the fields of active pharmaceutical ingredients and formulations, accelerate the research and commercialization of key generic drug products, continuously improve the operational management capabilities of generic drug products in technology research and development, product registration, intellectual property, GMP production, etc., and strive to achieve the approval and listing of generic drug products with certain competitiveness and broad market prospects in the medium and long term, enhancing the company's competitive position in the industry.

 

 

 

At the same time, with the development of the biopharmaceutical industry and the introduction of national encouraging policies, the company has begun to strategically layout in the field of biological cell drugs, expand the pipeline of innovative biological drugs, and strive to create a second growth curve in performance.

 

 

 

In terms of performance, the 2024 semi annual report shows that from January to June this year, the company achieved a revenue of 164 million yuan, a year-on-year decrease of 1.55%; The net profit attributable to the parent company was 25.1748 million yuan, a year-on-year decrease of 14.23%.